Silo Pharma (NASDAQ: SILO)ย announced that its board of directors authorized a share repurchase program toย acquireย up to $1 million of the companyโs common stock. Purchases may occur on the open market, through privately negotiated transactions or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The company reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025, according to its quarterly report for the periodย endedย Sept. 30, 2025. The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations, and the program does notย obligateย the company toย acquireย a specific number of shares and may be suspended orย discontinuedย at its discretion.
To view the full press release, visitย https://ibn.fm/gU3uZ
About Siloย Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyโs portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerโs disease and multiple sclerosis.ย Siloโs research is conducted in collaboration with leading universities and laboratories.
NOTE TO INVESTORS:โฏThe latest news and updates relating to SILO are available in the companyโs newsroom atโฏhttps://ibn.fm/SILO
About MissionIR
MissionIRย (โMIRโ) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visitย www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:ย https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered byย IBN
